A weekly podcast exploring medicine 4.0 as we launch into the 21st Century of health. Join us as we highlight the science and investment case for the different diseases and conditions that life sciences companies are trying to diagnose and cure.
A weekly podcast exploring medicine 4.0 as we launch into the 21st Century of health. Join us as we highlight the science and investment case for the different diseases and conditions that life sciences companies are trying to diagnose and cure.
In early 2023, one of the first two really big radiopharmaceutical drugs ran into a problem. Novartis' prostate cancer therapy Pluvicto, released only the year before, was suddenly in short supply, snarling up just in time treatment schedules.
In 2024 the supply chain problem is with the isotope Actinium 225, which *everyone* wants for clinical trials. RayzeBio has been a very famous victim, delaying a clinical trial because of the shortages.
In episode 2 of NUKED we explore where the nukes come from, and how biotechs large and small get their hands on them.
With GlyTherix CEO Dr Brad Walsh and Telix Pharmaceuticals CEO Dr Chris Behrenbruch, we look at a potential new front in the US-China tariff war, the Russia question, and how an early stage biotech and one with a product in the market organises its nuclear material supplies.
Produced by Rachel Williamson and Charis Palmer. Music and effect credits to Ziso, Inspector J, Seth Parson and Boom Library.
